Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Van Scoy LJ, Snyder B, Miller EL, Toyobo O, Grewel A, Ha G, Gillespie S, Patel M, Reilly J, Zgierska AE, Lennon RP. Public anxiety and distrust due to perceived politicization and media sensationalism during early COVID-19 media messaging. J Commun Healthc. 2021 Jul 31;14(3):193-205. doi: 10.1080/17538068.2021.1953934
Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Martin SA, Coon CD, McLeod LD, Chandran A, Arnold LM. Evaluation of the fibromyalgia diagnostic screen in clinical practice. J Eval Clin Pract. 2014 Apr;20(2):158-65. doi: 10.1111/jep.12102
Brown TM, Garg S, Chandran AB, McNett M, Silverman SL, Hadker N. The impact of 'best-practice' patient care in fibromyalgia on practice economics. J Eval Clin Pract. 2012 Aug 1;18(4):793-8.